|
|
Blood, 1 March 2005, Vol. 105, No. 5, pp. 1862-1866.
Prepublished online as a Blood First Edition Paper on November 4, 2004; DOI 10.1182/blood-2004-08-3373.
 Previous Article | Table of Contents | Next Article 
PERSPECTIVES
Punish the parent not the progeny
Lucy J. Elrick,
Heather G. Jorgensen,
Joanne C. Mountford, and
Tessa L. Holyoake
From the Section of Experimental Haematology, Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Glasgow, United Kingdom.
Abstract
Chronic myeloid leukemia (CML) is sustained by a rare population of primitive, quiescent, BCR-ABL+ cells and represents an excellent example of a malignancy in which tumor-initiating cells represent the key to disease eradication. CML is also the first malignancy for which targeted therapy has replaced conventional chemotherapy. Within a vast excess of proliferating progenitor cells that express breakpoint cluster region-abelson (BCR-ABL) and are exquisitely sensitive to the tyrosine kinase inhibitor imatinib mesylate (IM) resides a small population of quiescent leukemic cells that, despite higher levels of BCR-ABL transcripts, exhibits innate insensitivity to IM. These cells remain after IM therapy, even when apparently complete responses are achieved, and they probably explain molecular disease persistence. Although it can be argued that patients may survive for many years with low levels of leukemia still present, it is possible to achieve disease clearance at the molecular level following an allogeneic stem cell transplantation. The emergence of drug resistance with IM monotherapy also argues in favor of complete disease eradication that we believe should remain the ultimate therapeutic goal in CML. New approaches to the elimination of these primitive CML cells may thus be crucial to the development of curative strategies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. J. Druker
Translation of the Philadelphia chromosome into therapy for CML
Blood,
December 15, 2008;
112(13):
4808 - 4817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C. E. Leysath, H. Lu, S. Kimura, A. Ohsaka, M.-B. Rios, L. Calvert, et al.
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Mol. Cancer Ther.,
January 1, 2008;
7(1):
48 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Michor
Chronic Myeloid Leukemia Blast Crisis Arises from Progenitors
Stem Cells,
May 1, 2007;
25(5):
1114 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Puttini, A. M. L. Coluccia, F. Boschelli, L. Cleris, E. Marchesi, A. Donella-Deana, S. Ahmed, S. Redaelli, R. Piazza, V. Magistroni, et al.
In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells
Cancer Res.,
December 1, 2006;
66(23):
11314 - 11322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Hu, S. Swerdlow, T. M. Duffy, R. Weinmann, F. Y. Lee, and S. Li
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
PNAS,
November 7, 2006;
103(45):
16870 - 16875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood,
September 15, 2006;
108(6):
1809 - 1820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Jordanides, H. G. Jorgensen, T. L. Holyoake, and J. C. Mountford
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
Blood,
August 15, 2006;
108(4):
1370 - 1373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Copland, A. Hamilton, L. J. Elrick, J. W. Baird, E. K. Allan, N. Jordanides, M. Barow, J. C. Mountford, and T. L. Holyoake
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Blood,
June 1, 2006;
107(11):
4532 - 4539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aloisi, S. Di Gregorio, F. Stagno, P. Guglielmo, F. Mannino, M. P. Sormani, P. Bruzzi, C. Gambacorti-Passerini, G. Saglio, S. Venuta, et al.
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B
Blood,
February 15, 2006;
107(4):
1591 - 1598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. G. Jorgensen, M. Copland, E. K. Allan, X. Jiang, A. Eaves, C. Eaves, and T. L. Holyoake
Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate
Clin. Cancer Res.,
January 15, 2006;
12(2):
626 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Y. Lee, M.-L. Wen, A. Camuso, S. Castenada, K. Fager, C. Flefleh, I. Inigo, R. Luo, D. Kan, V. Manne, et al.
Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
1993 - 1993.
[Abstract]
|
|
|
|
|
|
|
J. Cortes and H. Kantarjian
New Targeted Approaches in Chronic Myeloid Leukemia
J. Clin. Oncol.,
September 10, 2005;
23(26):
6316 - 6324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Ilaria Jr.
Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues
Hematology,
January 1, 2005;
2005(1):
188 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
